Despite the widespread adoption of recommended anticoagulation intensity ranges during
percutaneous coronary intervention (PCI), there are limited randomized clinical trials
testing specific targets for activated clotting times (ACT). The primary research hypothesis
is that in the modern cardiac catheterization laboratory, where PCI procedural duration is
relatively short, radial access with small caliber equipment is preferable, and where rates
of intracoronary stenting and dual antiplatelet therapy use is high, lower ACT targets, as
compared with higher ACT targets, will be associated with lower rates of bleeding while
having similar rates of ischemic events.